We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $1.5B
1-Year Est. Return 518.95%
This Fund
S&P 500
This Quarter Est. Return
+50.03%
1 Year Est. Return
+518.95%
3 Year Est. Return
+1,728.44%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$297M
AUM Growth
+$78.8M
Cap. Flow
-$4.46M
Cap. Flow %
-1.5%
Top 10 Hldgs %
99.8%
Holding
13
New
–
Increased
3
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.79M
2
LQDA icon
Liquidia Corp
LQDA
+$8.04M
3
YMAB
Y-mAbs Therapeutics
YMAB
+$5.93M

Top Sells

Rank Stock Value
1
EOLS icon
Evolus
EOLS
+$3.27M
2
LAB icon
Standard BioTools
LAB
+$1.24M
3
VRCA icon
Verrica Pharmaceuticals
VRCA
+$1.01M
4
ADMA icon
ADMA Biologics
ADMA
+$460K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$7.72B
$125M 42.03%
10,360,945
+1,117,318
+12% +$8.04M
ALIM
2
DELISTED
Alimera Sciences
ALIM
$72.7M 24.53%
16,835,154
– –
ANIK icon
3
Anika Therapeutics
ANIK
$202M
$24.5M 8.26%
1,081,360
– –
EXEL icon
4
Exelixis
EXEL
$14.2B
$21.8M 7.37%
910,730
– –
LAB icon
5
Standard BioTools
LAB
$311M
$15.6M 5.25%
7,042,413
-580,000
-8% -$1.24M
EOLS icon
6
Evolus
EOLS
$410M
$13.9M 4.68%
1,317,856
-365,980
-22% -$3.27M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.14B
$9.84M 3.32%
441,833
+437,000
+9,042% +$9.79M
YMAB
8
DELISTED
Y-mAbs Therapeutics
YMAB
$7.15M 2.41%
1,048,425
+1,025,104
+4,396% +$5.93M
VRNA
9
DELISTED
Verona Pharma
VRNA
$3.64M 1.23%
183,064
– –
ADMA icon
10
ADMA Biologics
ADMA
$2.04B
$2.14M 0.72%
473,087
-124,426
-21% -$460K
SCTL
11
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$592K 0.2%
1,689,768
– –
VRCA icon
12
Verrica Pharmaceuticals
VRCA
$92.8M
– –
-25,959
Closed -$1.01M
ICPT
13
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-1,200,000
Closed -$22.2M

Similar funds

BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
JFGLC
Johnson Financial Group LLC (Colorado) Denver, Colorado $1.5B AUM 16.09% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.5B AUM 20.3% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
RCW
Rheos Capital Works Tokyo, Japan $1.5B AUM 47.78% 1-Year Est. Return

Caligan Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Caligan Partners held 13 positions worth $297M, up 36% from $218M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caligan Partners's Q4 2023 filing shows 3 increased, 3 reduced and 2 closed positions. The largest sale was Evolus, an estimated $3.27M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 90% a quarter earlier.

  • Caligan Partners added most to Agios Pharmaceuticals in Q4 2023, an estimated $9.79M increase.
  • Caligan Partners's biggest Q4 2023 reduction was Evolus, cutting an estimated $3.27M.
  • Caligan Partners fully exited Verrica Pharmaceuticals in Q4 2023, selling an estimated $1.01M.
  • Caligan Partners's ten largest holdings make up 100% of its $297M portfolio in Q4 2023.
  • Caligan Partners opened 0 new positions and closed 2 in Q4 2023.
  • Caligan Partners's portfolio value rose 36% quarter-over-quarter to $297M.

Based on Caligan Partners's 13F filing for Q4 2023, filed 14 Feb 2024.